Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice

International Psychogeriatrics

Volumn 20, Issue 4, 2008, Pages 800-806

  Umegaki, Hiroyuki ^a   Itoh, Akio ^a   Suzuki, Yusuke ^a   Nabeshima, Toshitaka ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Clinical dementia rating; Donepezil

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HUMAN; JAPANESE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PRESCRIPTION; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; JAPAN; KAPLAN-MEIERS ESTIMATE; LONG-TERM CARE; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; PSYCHOMETRICS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 43949104122     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610208007011     Document Type: Article

References (10)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
2. Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Systematic Review, 25, CD005593.
3. Blennow, K., de Leon, M. J. and Zetterberg, H. (2006). Alzheimer's disease. Lancet, 368, 387-340.
4. Evans, M., Ellis, A., Watson, D. and Chowdhury, T. (2000). Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. International Journal of Geriatric Psychiatry, 15, 50-53.
5. Frankfort, S. V. et al. (2005). Discontinuation of rivastigmine in routine clinical practice. International Journal of Geriatric Psychiatry, 20, 1167-1171.
6. Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. and Martin, R. L. (1982). A new clinical scale for the staging of dementia. British Journal of Psychiatry, 140, 566-567.
7. Mauskopf, J. A., Paramore, C., Lee, W. C. and Snyder, E.H. (2005). Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. Journal of Managed Care Pharmacy, 11, 231-251.
8. Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43, 2412.
9. Suh, D. C., Thomas, S. K., Valiyeva, E., Arcona, S. and Vo, L. (2005). Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs & Aging, 22, 695-670.
10. Umegaki, H., Suzuki, Y, Kuzuya, M. and Iguchi, A. (2007). Attitudes of Japanese general practitioners towards referrals of patients with dementia. Nippon Ronen Igakkai Zasshi, 44, 102-106.